India, Dec. 11 -- Alembic Pharmaceuticals Ltd announced on Thursday that it has received final approval from the US Food & Drug Administration (USFDA) for its generic version of Loteprednol Etabonate and Tobramycin ophthalmic suspension, a combination medicine used to treat eye infections.
The approval covers Alembic's Abbreviated New Drug Application (ANDA) for the ophthalmic suspension in 0.5%/0.3% strength, available in 5 mL and 10 mL pack sizes, the company said in a regulatory filing.
Alembic also received a Competitive Generic Therapy (CGT) designation for this product. With the approval, the company will be eligible for 180 days of CGT exclusivity upon commercial launch.
Published by HT Digital Content Services with permission fro...